Literature DB >> 21724256

MicroRNA-193b regulates c-Kit proto-oncogene and represses cell proliferation in acute myeloid leukemia.

Xiao-ning Gao1, Ji Lin, Li Gao, Yong-hui Li, Li-li Wang, Li Yu.   

Abstract

Mutations and/or overexpression of c-Kit proto-oncogene frequently occur in subsets of acute myeloid leukemia (AML) and contribute to abnormal cell proliferation and poor outcomes. We showed that c-Kit expression was subject to post-transcriptional regulation by microRNA (miRNA)-193b. Notably, miR-193b was significantly down-regulated in the examined AML cells and its levels were inversely correlated with c-Kit levels. Restoration of miR-193b expression in AML cells resulted in distinctly reduced c-Kit expression and inhibited cell growth. These data reveal a role for miR-193b dysregulation in myeloid leukemogenesis and the therapeutic promise of regulating miR-193b expression for c-Kit-positive AML.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21724256     DOI: 10.1016/j.leukres.2011.06.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

Review 1.  Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.

Authors:  Asfar S Azmi; Frances W J Beck; Bin Bao; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

2.  Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.

Authors:  Sheila Mansouri; Qun Pan; Benjamin J Blencowe; Julie M Claycomb; Lori Frappier
Journal:  J Virol       Date:  2014-07-16       Impact factor: 5.103

3.  Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.

Authors:  Haili Huang; Min Hu; Peng Li; Caijie Lu; Mingyi Li
Journal:  Tumour Biol       Date:  2014-10-15

4.  microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia.

Authors:  R Su; L Dong; D Zou; H Zhao; Y Ren; F Li; P Yi; L Li; Y Zhu; Y Ma; J Wang; F Wang; J Yu
Journal:  Oncogene       Date:  2016-04-18       Impact factor: 9.867

Review 5.  Non-coding RNAs: are they the protagonist or antagonist in the regulation of leukemia?

Authors:  Mrinnanda Bhattacharya; Ravi Kumar Gutti
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 6.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

7.  Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate.

Authors:  My Wintzell; Lina Löfstedt; Joel Johansson; Anne B Pedersen; Jonas Fuxe; Maria Shoshan
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

8.  Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells.

Authors:  Haruo Nakano; Yoji Yamada; Tatsuya Miyazawa; Tetsuo Yoshida
Journal:  Int J Oncol       Date:  2013-04-15       Impact factor: 5.650

9.  Identification and characterization of microRNAs in white and brown alpaca skin.

Authors:  Xue Tian; Junbing Jiang; Ruiwen Fan; Haidong Wang; Xiaolin Meng; Xiaoyan He; Junping He; Hongquan Li; Jianjun Geng; Xiuju Yu; Yunfei Song; Danli Zhang; Jianbo Yao; George W Smith; Changsheng Dong
Journal:  BMC Genomics       Date:  2012-10-16       Impact factor: 3.969

10.  MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1.

Authors:  Michelle Lenarduzzi; Angela B Y Hui; Nehad M Alajez; Wei Shi; Justin Williams; Shijun Yue; Brian O'Sullivan; Fei-Fei Liu
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.